Almirall has filed a patent for bispecific antigen-binding molecules targeting IL-13/IL-13R and OX40L/OX40 for treating dermatological diseases like atopic dermatitis. The invention includes pharmaceutical compositions and treatment methods. GlobalData’s report on Almirall gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Almirall, NSAID cancer drugs was a key innovation area identified from patents. Almirall's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application US20230374158A1 discloses a bispecific antigen-binding molecule that includes a first antigen binding domain targeting IL-13 or IL-13R and a second antigen binding domain targeting OX40L or OX40. This molecule is designed to specifically bind to both IL-13/IL-13R and OX40L/OX40, thereby antagonizing signaling from both IL-13 and OX40L.
Furthermore, the patent application describes the use of this bispecific antigen-binding molecule in treating various diseases and conditions associated with IL-13 and/or OX40L, such as dermatological diseases, asthma, cardiovascular diseases, cancer, and inflammatory bowel disease. The method involves administering the molecule to a patient, potentially in combination with other medications or treatment methods. The molecule can be in the form of a bispecific antibody, with specific configurations like IgG-like bispecific antibodies or dual-variable domain immunoglobulin (DVD-Ig) bispecific antibodies. This innovation opens up new possibilities for targeted therapy in a range of medical conditions, offering a promising avenue for future research and development in the field of biopharmaceuticals.
To know more about GlobalData’s detailed insights on Almirall, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
